Trevigen/Cultrex®基膜基质,类型3/3632-001-02/1 ml,2 x 5 ml,5 ml

价格
¥700.00
货号:3632-001-02
浏览量:127
品牌:Trevigen
服务
全国联保
正品保证
正规发票
签订合同
商品描述

Description

Cultrex®BasementMembraneExtract(BME)isasolubleformofbasementmembranepurifiedfromEngelbreth-Holm-Swarm(EHS)tumor.Thisextractprovidesanaturalextracellularmatrixhydrogelthatpolymerizesat37°Ctoformareconstitutedbasementmembrane.Basementmembranesarecontinuoussheetsofspecializedextracellularmatrixthatformaninterfacebetweenendothelial,epithelial,muscle,orneuronalcellsandtheiradjacentstromaandthatplayanessentialroleintissueorganizationbyinfluencingcelladhesion,migration,proliferation,anddifferentiation.ThemajorcomponentsofBMEincludelaminin,collagenIV,entactin,andheparansulfateproteoglycans.

Cultrex®BMEType3isphysiologicallyalignedwiththeinvivoenvironmentandisrecommendedforxenografts,tumorgrafts,andotherinvivoapplications.

Qualitycontrolspecifications:

  • Mousecoloniesareroutinelyscreenedforpathogensusing mouseantibodyproduction(MAP)testing.
  • Engelbreth-Holm-Swarm(EHS)tumorisLDEV-free.
  • PathClear®–testednegativebyPCRfor 17bacterialandvirusstrainstypicallyincludedinmouseantibodyproduction(MAP)testing,plus13additionalmurineinfectiousagentsincludingLDEV,foratotalof31organismsandviruses.
  • Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
  • Endotoxinconcentration≤8EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
  • Proteinconcentrationof12–18mg/ml.
  • NomycoplasmacontaminationdetectedbyPCR.
  • ProvidedinRoswellParkMemorialInstituted(RPMI) mediumwith10µg/mlgentamycin.
  • GelstABIlitytestedforaperiodof14daysat37°C.
  • BIOLOGicalactivitydeterminedforeachlot:
    • TumorGrowthAssay–BMEType3supportsproliferationandgrowthofbreastcancercells(MCF7)embeddedinthematrixforminimumof8days.

Catalog#3632-010-02includes: 
CatalogNumberDescriptionQty
3632-005-02Cultrex®BasementMembraneExtract,Type3,PathClear®2

GeneticIdentificationofSEMA3FasanAntilymphangiogenicMetastasisSuppressorGeneinHeadandNeckSquamousCarcinoma
ColleenL.Doçi,ConstantinosM.Mikelis,MichailS.Lionakis,AlfredoA.Molinolo,andJ.SilvioGutkind
CancerRes.,Jul2015;75:2937–2948.
http://cancerres.aacrjournals.org/cgi/content/abstract/75/14/2937

Trevigen,Inc.是一家发展迅速的生物技术公司,致力于开发用于癌症研究,药物发现,遗传毒理学,再生医学和干细胞研究的产品和技术。我们提供试剂盒和试剂,用于研究DNA损伤和修复,细胞凋亡,氧化应激,癌细胞行为,3D培养和干细胞。该公司获得了美国国立卫生研究院(National Institutes of Health)多项SBIR资助。